Pacira Prepares IPO, Reports Phase III Data for Exparel
By Catherine Shaffer
Tuesday, January 18, 2011
Pacira Pharmaceuticals Inc. has big plans for 2011. The Parsippany, N.J.-based company expects to make an initial public offering with expected net proceeds of up to $65.9 million to get its lead analgesic candidate Exparel (bupivacaine) off the ground.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.